Ocrevus (Ocrelizumab) 300mg/10ml
First and only FDA-approved treatment for primary progressive MS (PPMS). Also approved for relapsing MS. Genuine Roche product at 50-70% below US retail pricing.
What is Ocrelizumab? Understanding the Active Ingredient
Ocrelizumab (INN) is a humanized anti-CD20 monoclonal antibody developed by Roche/Genentech. It selectively targets and depletes CD20-positive B lymphocytes — a key driver of inflammation and neurodegeneration in multiple sclerosis. Unlike Rituximab (a chimeric antibody), Ocrelizumab's humanized design results in significantly fewer infusion-related reactions and improved tolerability.
Ocrevus was approved by the FDA in March 2017 as the first and only disease-modifying therapy for PPMS, based on the landmark ORATORIO trial. It also demonstrated superiority over interferon beta-1a (Rebif) in two Phase III trials (OPERA I and OPERA II) for relapsing MS, reducing annualized relapse rates by 46-47%.
The convenience of twice-yearly dosing (every 6 months after initial loading) versus daily/weekly alternatives has made Ocrevus one of the most prescribed MS therapies globally, with over 300,000 patients treated worldwide since approval.
Why Buy Ocrevus From Pharmacy Remedy?
100% Genuine Roche
Sourced from authorized Roche distributors with Certificate of Authenticity and batch traceability
Cold Chain Validated
2-8°C temperature-controlled shipping with continuous monitoring and deviation alerts
50-70% Below US Price
Save $35,000-$50,000/year vs US retail pricing through international sourcing
Global Delivery
Ship to UAE, Middle East, Europe, Asia with customs documentation and DDP options
Ocrevus vs Other MS Treatments — 2026 Comparison
| Feature | Ocrevus (Ocrelizumab) | Kesimpta (Ofatumumab) | Tysabri (Natalizumab) |
|---|---|---|---|
| Target | CD20+ B cells | CD20+ B cells | α4-integrin |
| PPMS Approved | ✅ Yes (first ever) | ❌ No | ❌ No |
| Route | IV infusion | SC injection | IV infusion |
| Frequency | Every 6 months | Monthly | Every 4 weeks |
| ARR Reduction | 46-47% vs IFNβ-1a | 50.5% vs teriflunomide | 68% vs placebo |
| PML Risk | Very rare | Very rare | Higher risk (JCV+) |
| US Annual Cost | $65,000-$70,000 | $83,000+ | $90,000+ |
| Our Price | 50-70% savings | N/A | Available |
Clinical Evidence — Landmark Trials
OPERA I
46% ARR reduction vs IFNβ-1a
Relapsing MS, N=821, p<0.001
OPERA II
47% ARR reduction vs IFNβ-1a
Relapsing MS, N=835, p<0.001
ORATORIO
24% disability progression reduction
PPMS, N=732, p=0.0321 — First PPMS approval
Ocrevus Dosing & Administration Guide
Initial Dose (Loading)
300mg IV infusion on Day 1, followed by 300mg IV infusion on Day 15 (two infusions, 2 weeks apart)
Subsequent Doses
600mg IV infusion every 6 months (24 weeks), starting 6 months after the first dose of the initial treatment
Pre-Medication Required
Methylprednisolone 100mg IV ~30 min prior + antihistamine (diphenhydramine) 30-60 min prior ± acetaminophen
Storage
Store at 2-8°C (36-46°F). Do not freeze or shake. Protect from light. After dilution: use within 24 hours (8 hours at room temp or 24 hours refrigerated).
Frequently Asked Questions About Ocrevus (Ocrelizumab)
Find answers to common questions about ordering, pricing, and shipping.